Stock RTGN RETINALGENIX TECHNOLOGIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages RetinalGenix Technologies Inc.

Equities

RTGN

US76133Y1055

Market Closed - OTC Markets
Other stock markets
 17:47:02 22/02/2024 GMT 		5-day change 1st Jan Change
3.5 USD +12.90% Intraday chart for RetinalGenix Technologies Inc. -.--% +13.27%
05-20 RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-01 RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
IN DIRETTA DAI MERCATI: Amplifon, Aena, Generali, Nexi, Stellantis, Terna, Zignago Vetro, Novo Nordisk, Pandora, ING, eBay...
RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
RetinalGeniX?? Technologies Inc. Contracts with Medsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Medical Advisory Board
RetinalGeniX Technologies Inc. Appoints Dessislava Boneva to its Board of Directors
RetinalGenix Technologies Inc. Appoints Stephen Tannenbaum to the Business Advisory Board
RetinalGenix Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
RetinalGeniX Technologies Inc. Announces the Submission of Two Provisional Patent Applications for Investigational Therapeutic Drugs
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam? Image Visualization Device
RetinalGeniX Technologies Inc. Announces Institutional Review Board Approves to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
RetinalGenix Technologies Inc. Appoints Fred Chasalow to the Medical Advisory Board of DNA-GPS
RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
RetinalGenix Technologies Inc. Auditor Raises 'Going Concern' Doubt
RetinalGenix Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
RetinalGenix Technologies Inc. Appoints Vinay Mehindru to its Board of Directors
RetinalGenix Technologies Inc. acquired DNA/GPS Inc. from Lawrence Perich for $14 million.
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RTGN Stock
  4. News RetinalGenix Technologies Inc.
  5. Other languages